
Immuno-Biological Laboratories Co., Ltd.
4570.TJPXHealthcareBiotechnology
Latest quote
¥1,060
−¥20.00 · -1.85%
4570.T company overview
Regular session · JST · Market data may be delayed.
Company profile
Company websiteImmuno-Biological Laboratories Co., Ltd. (IBL) is a global entity dedicated to the research, development, production, and distribution of immunological reagents. The company's diverse offerings include ELISA assay kits designed for the precise quantitative measurement of targeted substances, alongside comprehensive research support services focusing on areas such as Alzheimer's disease, metabolic syndrome, and cancer. IBL also caters to specific client needs through customized services for antibody production and the development of bespoke ELISA systems. A prominent service is LipoSEARCH, which provides tailored lipoprotein profiling and analysis utilizing gel-filtration high-performance liquid chromatography. This advanced method allows for the in-depth examination of even minute plasma or serum samples from both humans and small animals, supporting a broad spectrum of research, including lipid metabolism, the creation of pharmaceuticals for lifestyle-related diseases, functional food development, and clinical investigations. For animal health, IBL offers LipoTEST, a diagnostic and health screening tool for veterinary clinics, complemented by personalized biomarker testing services for lifestyle-related conditions. Furthermore, the company operates an innovative protein production division that leverages transgenic silkworms. This technology is instrumental in manufacturing antibodies for research and diagnostic applications, human collagen for cosmetic use, proteins for drug development, and other specialized proteins. Established in 1982, Immuno-Biological Laboratories Co., Ltd. is headquartered in Fujioka, Japan.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- JP
- CEO
- Tsutomu Seito
- Listed since
- Aug 15, 2007
- Employees
- 54
Market position
Day range
Current ¥1,060
52-week range
Current ¥1,060
- Open
- ¥1,062
- Previous close
- ¥1,080
- Volume
- 69.7K
- 0.6× average
- Average volume
- 115.33K
- Average daily volume
- Market cap
- 9.87B JPY
- Beta
- -0.02
- Market reference 1
- 50-day average
- ¥976.34
- +8.57% above average
- 200-day average
- ¥1,353.48
- -21.68% below average
Financials
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1B JPY | 969.53M JPY | 816.7M JPY | 794.62M JPY | 647.58M JPY |
| Cost of goods sold | 304.71M JPY | 341.19M JPY | 299.41M JPY | 267.91M JPY | 270.88M JPY |
| Gross profit | 700.28M JPY | 628.34M JPY | 517.29M JPY | 526.71M JPY | 376.7M JPY |
| Research and development | 120.05M JPY | 119.03M JPY | 129.98M JPY | 179.66M JPY | 188.59M JPY |
| Selling, general, and administrative | 298.95M JPY | 299.97M JPY | 274.34M JPY | 295M JPY | 310M JPY |
| Operating expenses | 419M JPY | 419M JPY | 412.99M JPY | 468.33M JPY | 498.91M JPY |
| Interest income | 1.79M JPY | 454K JPY | 93K JPY | 1.36M JPY | 487K JPY |
| Interest expense | 1.33M JPY | 1.26M JPY | 1.13M JPY | 1.07M JPY | 641K JPY |
| Depreciation and amortization | 18.54M JPY | 15.43M JPY | 2.33M JPY | — | 122M JPY |
| Operating income | 281.28M JPY | 209.35M JPY | 104.3M JPY | 58.37M JPY | −122.22M JPY |
| Net income | 329.02M JPY | 249.05M JPY | 186.69M JPY | −289.73M JPY | −258.77M JPY |
Company facts updated Aug 24, 2026.
Earnings
- Latest EPS result
- 10.76
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
4570.T peers
Continue in GoAI
Research 4570.Tresearch.disclaimer





